Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


October 3rd, 2023

Pharmaxis (Syntara) Sells off Mannitol Business

Not surprisingly, Pharmaxis (PXS: $0.035) will sell off its mannitol drug business. The acquiror is Australian-based Arna Pharma.


CUV 943
September 19th, 2023

Clinuvel Pharmaceuticals v. Nanosonics

Two highly successful life science companies that have emerged in the last decade in Australia are Clinuvel Pharmaceuticals (CUV: $15.64) and Nanosonics (NAN: $4.37). Whilst one is a pharmaceutical company and the other sells medical products (the Trophon disinfection instrument for ultrasound probes), there are several commonalities between the two businesses which make a comparison worthwhile.

September 19th, 2023

Polynovo v AROA Biosurgery

By most measures, except for net profit, Polynovo (PNV: $1.28) has delivered an exceptionally strong year in FY2023. Revenue has increased by 59% to $66.5 million, the numbers of hospitals/customers has increased by 168 to 638, and its staff numbers have also surged by 66 to 218.


respiri 944
September 4th, 2023

Respiri Signs Three US Remote Patient Monitoring Contracts

Having wrapped up the acquisition of Access Managed Services, Respiri (RSH: $0.03) has quickly moved to securing new initial patient monitoring contracts.



September 4th, 2023

Disappointing Half Year Sales for Cogstate; Pipeline for New Contracts at All-time High Levels

A robust 1H23 in recorded clinical trial sales amounting to US$27.3M was followed by a reduction of approximately 75% in 2H23, with sales totalling just US$6.7M. This marks a decline in overall clinical trial sales of 59% from the record reported in FY22 of US$82.5 million.

September 4th, 2023

Imugene to Acquire Fourth Technology Platform

Imugene (IMU: $0.065) has announced it will acquire its fourth technology platform in cancer immunotherapy. The company is in-licensing an allogeneic CAR-T program, called Azer-Cel, from US company Precision Biosciences.

CUV 944
September 4th, 2023

Robust Growth Expected to Continue for Clinuvel Pharmaceuticals

For FY2023, Clinuvel Pharmaceuticals (CUV: $18.15) achieved total revenues of $83 million, which was up 24% on the previous year. The net profit for the year increased by 47% to $30.6 million. The company finished the year with $157 million in cash.

August 11th, 2023

2023 Bioshares Biotech Summit Coverage (Imugene)

Keynote address

Dr. Yuman Fong is a surgical oncologist at the City of Hope Medical Centre and was Keynote Speaker at this year's Bioshares Biotech Summit. As a clinician and scientist, while Dr. Fong's "day job" is surgery, he also works as an immuno-oncology researcher with his work partnered with Imugene (IMU: $0.089). Dr. Fong also has industry facing experience, having held regulatory roles in the approval process for immunotherapies and experience working with Genentech.

August 11th, 2023

Pharmaxis - Meaningful Impact on Bone Marrow in Myelofibrosis Study

Pharmaxis (PXS: $0.05) has released interim results from its Phase II study with PXS-5505 in patients with myelofibrosis. Results from the first 10 patients who completed six months of treatment are now available.

respiri 942
August 11th, 2023

Respiri - Targeting Cashflow Positive in 2024

Respiri (RSH: $0.034) CEO Marjan Mikel said that for 40 years the healthcare system has been seeking to reduce healthcare costs by moving patients out from expensive treatment settings into cheaper areas such as GP clinics or treatment in the home. However, the same narrative remains unchanged and largely unsuccessful, something Respiri is seeking to change.

DMX 942
August 11th, 2023

Dimerix in Partnering Discussions, Interim Results out March 2024

Dimerix (DXB) CEO Nina Webster had encouraging news to share regarding the status of DXB's ACTION3 trial at the 17th annual Bioshares Biotech Summit. The pivotal Phase III trial is a randomised, double-blind, placebo-controlled trial of the efficacy and safety of DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS), a rare form of kidney disease.

July 21st, 2023

Neuren Pharmaceuticals Moves to Worldwide License for Trofinetide and NNZ-2591 with Acadia

Neuren Pharmaceuticals (NEU: $14.20) announced this week a significant expansion of its partnership with US biopharmaceutical company Acadia Pharmaceuticals (NASDAQ: ACAD). The agreement not only sees Acadia's exclusive licence for trofinetide in North America expand to a worldwide licence, but also Acadia's acquisition of the exclusive worldwide licence for NNZ-2591 in Rett Syndrome and Fragile X Syndrome.

pharmaxis 939
June 6th, 2023

Mixed Results from Pharmaxis' Scar Treatment Study

Pharmaxis (PXS: $0.048) recently wrapped up its PXS-6302 Solaria 2 Trial, showing "encouraging" results. The double-blind placebo-controlled study followed 42 adult patients with an established scar (>1 year old) for three months. Patients were treated with PXS-6302 with the collagen content of scarred skin assessed using biopsy. Patient and Observer Scar Assessment Scale (POSAS) measurements were also taken for both experimental and control groups before and after the course of treatment.

ebr systems 2
June 6th, 2023

EBR Systems Achieves Positive Results in Pivotal Study

EBR Systems (EBR: $1.12) is developing the world's first wireless pacing system for the left ventricle of the heart. The company recently announced positive clinical results from its pivotal US study which opens the path for FDA registration of the device.

immuron 938
May 19th, 2023

Immuron Receives FDA Clearance for Third US Study

The FDA has removed a clinical hold on Immuron's (IMC: $0.08) study for a new therapeutic to prevent infectious diarrhea, caused by two bacteria, E. coli and Campylobacter.

May 19th, 2023

EBR Systems Pivotal Trial Results to be Announced this Week

The results from EBR Systems'(EBR: $0.905) pivotal study will be presented at the Heart Rhythm 2023 meeting this weekend. EBR is holding a webinar this Monday morning to discuss the results.

May 19th, 2023

Dimerix to Raise $12 Million in Difficult Market

Dimerix (DXB: $0.072) is seeking to raise $12 million at $0.08 per share. Confirming the difficult capital markets, the raise will include a rights issue and also convertible note financing.

CHM 938
May 19th, 2023

Chimeric Therapeutics Opens $6.3 Million Capital Raise

Chimeric Therapeutics (CHM: $0.039) has announced a capital raise for up to $6.3 million, which comprises of a $1.04 million placement to board and management and a $5.25 million SPP.

May 19th, 2023

Anteris Technologies - Expands Programs to Mitral and Tricuspid Valve Repair

Anteris Technologies (AVR: $23.00) finished the March quarter with $32 million in cash following a $35 million capital raise in the quarter at $24 per share. The company's net cash outflow for the last three quarters from operational and investment activities was $14.5 million.

May 19th, 2023

Cogstate - Eli Lilly's Donanemab Confirms Benefit of Beta Amyloid Drugs for Alzheimer's

Eli Lilly has achieved unequivocally positive efficacy outcomes from its Phase III study with the drug candidate donanemab for the treatment of early stage Alzheimer's disease. It's the second positive late stage study result in the last year, with Eisai & Co achieving similarly positive results with its drug Leqembi (lecanemab).